AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase III study titled ‘A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES).’ The study aims to assess the efficacy and safety of Benralizumab, a biological treatment, in patients with HES, a rare and chronic condition characterized by high levels of eosinophils.
The intervention being tested is Benralizumab, administered via subcutaneous injection every four weeks. Its purpose is to reduce eosinophil levels and manage symptoms in patients with HES.
This interventional study uses a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, comparing Benralizumab against a placebo.
The study began on July 20, 2020, and is currently active but not recruiting. The primary completion date is yet to be determined, with the last update submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
The outcome of this study could significantly impact AstraZeneca’s stock performance by potentially expanding its portfolio with a new treatment for HES. Positive results may boost investor confidence, while also influencing the competitive landscape in the biopharmaceutical industry.
The study is ongoing, and further details are available on the ClinicalTrials portal.